Health Care [ 5/12 ] | Biotechnology [ 30/73 ]
NASDAQ | Common Stock
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders.
Its product candidate includes verekitug, which is in Phase 2 clinical development for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps, as well as in Phase I clinical trial for treating chronic obstructive pulmonary disease.
The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 6, 25 | -0.74 Increased by +93.38% | -0.61 Decreased by -21.31% |
| May 6, 25 | -0.51 | -0.48 Decreased by -6.25% |
| Mar 12, 25 | -0.41 | - |
| Nov 7, 24 | -6.96 | -3.65 Decreased by -90.68% |
| Aug 28, 24 | -11.18 | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 937.00 K Increased by +83.73% | -39.97 M Decreased by -172.29% | Decreased by -4.27 K% Decreased by -48.20% |
| Mar 31, 25 | 566.00 K Decreased by -11.56% | -27.27 M Decreased by -150.32% | Decreased by -4.82 K% Decreased by -183.05% |
| Dec 31, 24 | 613.00 K Increased by +36.22% | -21.24 M Decreased by -79.51% | Decreased by -3.47 K% Decreased by -31.78% |
| Sep 30, 24 | 607.00 K Decreased by -2.25% | -15.99 M Decreased by -415.54% | Decreased by -2.63 K% Decreased by -427.43% |
| Jun 30, 24 | 510.00 K - | -14.68 M - | Decreased by -2.88 K% - |
| Mar 31, 24 | 640.00 K - | -10.89 M - | Decreased by -1.70 K% - |
| Dec 31, 23 | 450.00 K - | -11.83 M - | Decreased by -2.63 K% - |
| Sep 30, 23 | 621.00 K - | -3.10 M - | Decreased by -499.52% - |